Sagar Lonial, MD - Rebooting the Treatment of Relapsed/Refractory Multiple Myeloma: A New Look at Novel Cereblon-Targeted Agents

Please visit answersincme.com/NMC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses rationale for—and clinical impact of—cereblon (CRBN) E3 ligase modulators (CELMoDs) in treating relapsed/refractory multiple myeloma (RRMM), including clinical considerations for their future use. Upon completion of this activity, participants should be better able to: Recognize the clinical rationale for investigating novel therapies to address unmet treatment needs for relapsed/refractory multiple myeloma; Review the biologic rationale for targeting cereblon with novel therapies for RRMM; Describe the clinical impact of emerging CRBN E3 ligase modulators in patients with RRMM; and Outline clinical considerations for the integration of CRBN E3 ligase modulators in the future management of RRMM.